Skip to main
NEPH
NEPH logo

Nephros Inc (NEPH) Stock Forecast & Price Target

Nephros Inc (NEPH) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nephros Inc. is forecasted to experience revenue growth, with anticipated revenues of $3.6 million in 4Q24, representing a 12% increase from the previous year, alongside a reduced net loss per share, indicating improved financial health. The company has successfully maintained overhead expenses while enhancing its gross margins to 61.9% in 1Q24, which reflects operational efficiency and effective cost management. Additionally, recurring revenue growth and a rebound in emergency response orders have contributed to a significant improvement in adjusted EBITDA, highlighting strong performance in its core markets and a favorable outlook for future profitability.

Bears say

Nephros Inc. is projected to experience a 2% decline in revenue for full-year 2024, totaling $13.9 million, while still reporting a reduced net loss compared to the previous year. The company's cash reserves have diminished significantly from $4.3 million at the beginning of the year to $3.6 million by the end of the first quarter, primarily due to increased inventory costs and early bonus payments. Additionally, Nephros' valuation of 1.2X estimated 2024 revenues is substantially lower than that of its industry peers, which trade at ratios of 3X-4X, indicating potential undervaluation or lack of market confidence in the company's growth prospects.

Nephros Inc (NEPH) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nephros Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nephros Inc (NEPH) Forecast

Analysts have given Nephros Inc (NEPH) a Buy based on their latest research and market trends.

According to 2 analysts, Nephros Inc (NEPH) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nephros Inc (NEPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.